Over a decade of commitment, Frontier Biotech has established a strong team with global vision and deep expertise, poised for international expansion. It has built a fully-integrated, state-of-the-art long-acting peptide drug innovation platform. In addition to the commercialization of Aikening™, a long-acting HIV fusion inhibitor, Frontier Biotech is advancing an array of clinical assets through its diversified R&D pipeline, with on-going clinical trials in China and the United States.

The company has established API and final drug product production capabilities and built state-of-the-art manufacturing plants in Nanjing, Sichuan and Shandong. These manufacturing sites comply with international pharmaceuticals manufacturing standards and are certified by US FDA, cGMP, EMA GMP and PICS.

Aikening^™ has received Marketing Authorization in China since 2018 and subsequent Marketing Authorizations were obtained in Ecuador, Cambodia, Malaysia, Azerbaijan and Kazakhstan.